Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302710 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9GPR84SIGMAR1 | |
| SCHEMBL302715 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9GPR84SIGMAR1 | |
| SCHEMBL303785 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9GPR84SIGMAR1 | |
| SCHEMBL302935 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9GPR84SIGMAR1 | |
| SCHEMBL304716 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9GPR84SIGMAR1 | |
| SCHEMBL303705 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9GPR84SIGMAR1 | |
| SCHEMBL302931 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9GPR84SIGMAR1 | |
| SCHEMBL304711 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9GPR84SIGMAR1 | |
| SCHEMBL303608 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9GPR84SIGMAR1 | |
| SCHEMBL303906 | 1.00 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9GPR84SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 733 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116848094-A | Tertiary amine lipid compounds and uses thereof | 华南理工大学 | 2023-10-03 | — | — | CN | claimed |
| WO-2023125184-A1 | TERTIARY AMINE LIPID COMPOUND AND USE THEREOF | 华南理工大学 | 2023-07-06 | — | — | WO | claimed |
| CN-1738829-B | New 2',5'-oligoadenylic acid analog | SANKYO CO | 2012-11-28 | — | — | CN | claimed |
| EP-0966456-B1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2003-04-02 | — | — | EP | claimed |
| WO-2000079312-A1 | HIGH REFRACTIVE INDEX COMPOSITIONS FOR OPHTHALMIC IMPLANTS | BAUSCH & LOMB SURGICAL, INC. (US) | 2000-12-28 | — | — | WO | claimed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | claimed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | claimed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | claimed |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| EP-4234609-B1 | METHODS FOR PURIFICATION, DETECTION AND QUANTIFICATION OF RESIDUAL PEI-BASED TRANSFECTION REAGENTS | POLYPLUS TRANSFECTION (FR) | 2024-07-17 | — | — | EP | disclosed |
| CN-118234717-A | Bicyclic heteroaromatic compounds and their use as pest control agents | PI工业有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4375280-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371985-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-22 | — | — | EP | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-4427640-A | Sequential process for extraction and recovery of vanadium and uranium from wet process acids | KERR-MCGEE CHEMICAL CORPORATION (US) | 1984-01-24 | — | — | US | disclosed |
| US-4329350-A | VASODILATORS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | CYP7A1, UGT1A3, UGT1A1 | CYP1A2 21/4885CYP2C19 58/4885CYP2C9 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.